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ABSTRACT A preliminary, cross-sectional study on the pattern of statins use in three hospitals in Jakarta was
conducted to see the responder rate of the patients who took statins. Data were taken from the
Medical Records from May-July 2004 of each hospital. The inclusion criteria were outpatients
diagnosed with dyslipidemia treated with statins either as first choice or add-on therapy to the other
lipid-lowering drugs given. Two hundred and forty three cases were recorded during the 3-month
period of examination, 127 male and 116 female. The average age of both group ofpatients were 56
:t 12 years (male) and 55 :t 12 years (female). The most commonly used statins as first choice and
as add-on was atorvastatin (38.1 %, and 1.6%, respectively), followed by rosuvastatin (20.5%),
fluvastatin (11.5%), pravastatin (10.7%); whereas lovastatin (0.4%) and simvastatin (3.7%) were
least prescribed. Patients' total cholesterol levels were reduced significantly (241 :t 57 vs 207 :t 38
mg/dL, p < 0.0001), whereas triglyceride levels were not significantly reduced (174 :t86 vs 160:t
71 mg/dL). Around 46% cases (72 out of 243 cases) met the NCEP ATP III goals on total
cholesterol level. The most common combinations used, with respect to atorvastatin, were
fenofibrate (11.3%), pravastatin (9.3%), rosuvastatin (3%), gemfibrozil (2%), whereas, with
regard to rosuvastati, were gemfibrozil (9%), ciprofibrate (5%), and atorvastatin (3%). Large
numbers of patients were not regularly checked up or low in compliance. In conclusion, statins
usage in some hospitals in Jakarta had been inappropriately used, due to multiple factors, such as,
prescribers, patients' aspects, and the national health system. Therefore, in order to observe the
efficacy of statins in clinical setting, a large scale study on the pattern of statin use should be
conducted.
Many studies reveal that low blood cho-
lesterol concentration substantially lowers the
incidence of myocard infarct and any other car-
diovascular diseases (Levine et aI, 1995; Hughes
1997).The first effort offered for patients to lower
their cholesterol level in blood is by changing life
styles, which include reducing body weight, more
vigorous daily activity and smoking cessation.
However, these efforts could only reduce the
cholesterol level up to 15%. For most of the cases,
pharmacological approach, in the end, is considered
by giving a specific lipid lowering drug. There are 5
classes of lipid-lowering drugs obtainable i.e. statins,
niacin, bile-acids binding resins, fibrates, and choles-
terol absorption inhibitor (ezetimibe) (Mahley arid
Bersot,2001].
Statins (3_0H-3-methylglutaryl-CoA reductase
inhibitor) are group of lipid lowering drugs, which
are very effective in lowering the coronary artery
incidence shown in many primary and secondary
prevention studies. There are now at least seven
types of statins, which are available in the market.
The first obtainable statins are lovastatin, pravastatin
and simvastatin, all of which have shown some
remarkable results on lowering the incidence of
cardiovascular diseases (Anonymous, 1999; LIPID,
1998;Heart ProtectionStudy Collabora-tive Group,
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2002;Ballantyne et al. 2003).The development of new
generation of statins is ever increased since the last 10
years; fluvastatin, atorvastatin and rosuvastatin are
some of the newly developed statins, which
according to the producers are somehow more
powerful and have less side effects.
Though in many controlled studies, with
very rigorous protocols, statins have proved to be
effective in lowering coronary heart diseases (CHDs),
however, the use of statins in clinical practice
especially in developing countries are not yet fully
explored, although in developed country such
assessment has been done recently (packham et aI,
2000). Thus, the aim of the study was to investigate
the pattern of statins' use in several hospitals in
Jakarta greater area.
MATERIALS AND METHODS
A cross-sectional data of medical records
from May to July 2004were taken from three private
hospitals in Jakarta greater area. The inclusion
criteria for selecting and collecting data are out-
patients diagnosed with hypercho-Iesterolemia or
hyperlipidemia either with or without any other
complications or accompa-nying diseases who are
treated with statins. The statins used can be either as
first choice or add-on to any other lipid lowering
drugs, such as fibrates or niacin. Responder is
defined as patient whose Total cholesterol level (Tq
during or after treatment meet the level as it is
suggested by the NCEP ATP ill criteria. Statistics
were used as long as data collected were appropriate
using SPSSverso11.0
RESULTS
At first, 256cases were collected, but, after re-
scrutinizing the data, for lacking of important items
such as date of follow-ups, dosage, etc, only 243cases
were included for the study.
The mean of patients' age was shown in
Table 1. As we see from the table, male and female
patients came from the same age group. However,
there was one patient whose age was only 17 years
old with total cholesterol level 243 mg/ dL. She.
probably had a genetic type of hypercholesterolemia
which could be assessed through genotyping.
The most commonly used statins as first
choice and as add-on to the subsequent cases was
depicted in Table 2. Atorvastatin (38.1% as first
choice and 1.6% as add-on) seems to be the most
prescribed statin, whereas lovastatin and simvastatin
were least prescribed.
Total cholesterol (Tq and Triglycerides (TG)
concentrations were depicted in Table 3 and 4. Only
84 out of 243 cases of Low-density lipoprotein
cholesterol (LDL-q level were regularly measured,
whereas, the measurements of High-density
lipoprotein cholesterol (HDL-C) were even more
scarce (18 cases). Therefore, due to the inadequate
data, both lipoprotein levels could not be shown and
analyzed.
With respect to the NCEP ATP ill criteria of
cholesterol levels, the effect of various statins on TC
and TG concentrations were depicted in Fig. 1 and 2.
The percentage of patients whose TC level meet the
criteria of ATP (responders) was shown in Table 5.
As it is often seen in the clinics, statins are
usually prescribed in combination with other lipid-
lowering drugs, such as fibrates, nicotinic acid and
recently with ezetimibe, as a cholesterol absorption
inhibitor. In this study, this combination was shown
in Table. 6.
All statins significantly decreased the plasma
TC level compared to the pretreatment level, but not
for TG. The most frequently prescribed statins were
atorvastatin (39.7%,97 cases), rosuvastatin (22.5%,55
cases), pravastatin (14.5%,37 cases), fluvastatin (13%,
34 cases), simvastatin (3.7%, 9 cases), lovastatin
(0.4%, 1 case), and the most frequent combination
used for atorvastatin was fenofibrate, whereas for
rosuvastatin was gemfibrozil.
Table 1. Demographic data of the patients
. Age (years) (Mean:!:SO)
NumQer of cases
Male
56 :!: 12
127
Female
55 :!: 12
116
Total
55 :!: 12
243
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Table 2.Themost frequently prescribedstatins in the particular hospitals setting
Type of statins As first choice As add-on
Simvastatin 3.7%
Pravastatin 10.7%
Fluvastatin 11.5%
Atorvastatin 38.1%
Rosuvastatin 20.5%
Lovastatin 0.4%
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Figure 1. The effect of various statins on the level of Total Cholesterol. The dotted line shows the minimum
level of TC according to the NCEP ATP ill goals.
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Figure 2. The effect of various statins on the level of Triglycerides. The dotted line shows the minimum
level of TC according to the NCEP ATP ill goals.
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Table 3. The effect of various statins on total cholesterol level
Type of statins Total Cholesterol (mgj dL; Mean:t SD)
Pre treatment During & Post treatment
Simvastatin 226.5 :t 45 190 :t 22.7
Pravastatin 220 :t 40 215 :t 40
Fluvastatin 236 :t 41.5 205 :t 28
Atorvastatin 227 :t 52.6 196 :t 35
Rosuvastatin 247 :t 109 206 :t 51
Total 241 :t 57 207 :t 38*
* p < 0.001
Table 4. The effect of various statins on triglycerides level
Type of statins Triglycerides (mgj dL; Mean:t SD)
Pre treatment During & Post treatment
Simvastatin 203.5 :t 45 136 :t 37
Pravastatin 138 :t 30 127 :t 74
Fluvastatin 234 :t 61.5 151 :t 60
Atorvastatin 141 :t 68 142 :t 68
Rosuvastatin 176 :t 61 159 :t 65
Total 174 :t 86 160 :t 71
Table 5. The percentage of responders in accordance with the ATP ill criteria
All type of statins
Simvastatin
Pravastatin
Fluvastatin
Atorvastatin
Rosuvastatin
Atorva + (prava;, fibrate,
gemfibrozil)
Percentage of responder population
46.45% (72 out of 155 cases)
0.65%
3.22%
1.33%
17.42%
5.16%
0.65%,0.65%,0.65%, respectively
Table 6. The most lipid-lowering drug combinations used with statins
Fenofibrate
Pravastatin
Rosuvastatin
Gemfibrozil
Fluvastatin
Ciprofibrate
Atorvastatin
Atorvastatin
(94 cases)
11.3% (11)
9.3% (9)
3.0% (3)
2.0% (2)
1.0% (1)
1.0% (1)
Rosuvastatin
(55 cases)
9.0% (5)
5.0% (3)
3.0% (2)
http://www.univpancasila.ac.id 7/27
PATTERN OF STATIN USE IN SEVERAL HOSPITALS IN JAKARTA. A CROSS SECTIONAL STUDY 227
DISCUSSION
From Figure 1 and Table 3 we can see that TC
level was significantly reduced. But, to some extent,
the decrease was not yet optimal. In this study, the
total cholesterol and triglyceride levels were lower
compared to the pretreatment level, though only
46.45% of patients whose total cholesterol level
achieved the NCEP ATP ill goal (See Table 5.). In
contrast, atorvastatin (17.42%)seemed to be the most
significant contributor which gave the result. This
-result, surprisingly, is lower than the other result
(Nash, 1996).Brown et al., (1998),however, showed
that a significant number of patients treated with
atorvastatin reached the target LDL cholesterol level
than patients treated with fluvastatin and lovastatin.
In this study, atorvastatin was the most frequently
prescribed drug in the three hospitals.
The results of many controlled trials on
dyslipidemia indicated that CHD mortality was
reduced as much as 30% to 40% when hyper-
holesterolemic patients were treated with moderate
dose of lipid-lowering drugs. Thus, it was very
important that the ultimate goal for treating patients
with hypercholesterolemia was that their cholesterol
level could achieve the NCEPATP ill goals.,
- Unfmtunately, according to Prlmatesta et al
(2000),only 1 out of 50 English adults used a lipid
lowering agent (30% of people with a history of
cardiovascular disease and 3% of people with a 10
year risk of coronary heart disease of >30%).And this
was also confirmed by Hulley (2000)and Packham et
al. (2000).As shown in these studies, patients who
supposed to be treated with statins accordingly
received no proper treatment.
As was depicted in Table 6, there were 11
cases where combination of statins with fibrate were
used. In addition, there were also combinations of
two different statins, like atorvastatin with pravas-
tatin (9 cases), and atorvastatin and rosuvastatin (3
cases). It was well documented elsewhere, that the
combinations of statins with other lipid-lowering
drugs, such as bile-acid binding resins, niacin were
beneficial, but, to put two statins together in one
therapy regime was not yet well practiced.
Unfortunately, some drug combinations were prone
to intensify their side effects.The most frequent side-
effects predicted were myopathy which could lead to
rhabdomyolysis (Duell et al, 1998; Garnett, 1995;
Miller & Spence 1998).In this study, it was not clear
whether the patients observed experienced some
effects resembling myopathy, while no notices were
seen in the medical record. Some studies revealed
that myopathy apparently occurred due to pharma-
codynamic and pharmacokinetics interactions
(Corsiniet al., 1999;Mahley& Bersot,2001)._
The measurement of the concentration of
lipoprotein cholesterol should comprise not only
total cholesterol, but LDL-C and HDL-C as well,
especially for patients who had other risk factors as
mentioned in NCEP ATP ill criteria. In this study,
quite a lot of patients had been checked only for their
TC level and triglyceride level, whereas the level of
HDL-C was also not properly checked. There were
28.2% (49 out of 174 patients) who had their
pretreatment HDL-C level ~ 40mg/ dL (data was not
shown), which was also considered as one of the
important predisposing factor for CHD (Ballantyneet
al., - 2003; Kreisberg, 2002; Kreisberg, 2003). Other
predisposing factors, such as BMI, smoking habits,
family history were not very well documented. As
suggested in the NCEP ATP ill guideline, all these
factors should always be taken into account for the
treatment of dyslipidemia.
On the other hand, many cases were difficult
to retrieve due to irregular check ups or no follow-
ups; therefore, these factors, at the end, gave an
incomplete information on the efficacyof the respec-
tive statins. There were some possible answers to this
problems, i.e. among others, lack of comprehensive
information from the care providers to the patients
on the importance of the continuity of the drugs
prescribed, and patients refused to come for check
ups due to economic backgrounds (Fairhurst &
Huby, 1998;Schwed et al, 1999).Furthermore, most of
the patients in Indonesia were not covered by
insurance, or patients who felt better due to various
reasons were refused to come for followups,
The choice of statins should be based on
efficacyand cost. Could the dose of a particular statin
reduce the patient's LDL-C to the target level? With
regards to the decrease of LDL-cholesterol level,
nowadays, a combination of statins and a cholesterol
absorption inhibitor i.e. 'ezetimibe, was proven to be
superior compared to statins alone or statins with
other lipid-lowering drugs, such as fibrates. The
combina-tion of ezetimibe and simvastatin could
reduce the LDL-C level up to 38% (Goldberg et al.,
2004),which gave a greater proportion of patients to
reach the target level according to the NCEPATP ill
criteria. Cost should be the next discerning factor, if
once drug treatment is initiated, it is almost always
lifelong (Ulrich et al, 2000). Combination of statins
and other lipid lowering drugs also had a beneficial
aspect which could reduce the possibility of statins'
http://www.univpancasila.ac.id 7/27
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side effectswhile the statin dosage used in combina-
tion was lower than statin monothe-rapy.
The use of evidence from controlled clinical
trials to support routine practice was obvious to be a
key factor of achieving a cost effective health service
(VanHout and Simoons, 2001).Treatment guidelines
offer the prescribers a rational way to choose and
maintain their treatment for particular diseases,
including hy-perlipidemia, but, nevertheless, doctors
should pursue the new trends and developments in
their respective areas, as in the treatment of lipid
disorders. The development and use of statins were
an example of the very rapid progression in the
management of dyslipidemia.
CONCLUSION
A cross-sectional study of pattern use of
statins in several hospital in Jakarta was conducted.
Although total cholesterol levels decreased
significantly, the responders rate was still small. The
dose of statins (rosuvastatin, fluvastatin) needs to be
increased to meet the therapeutic goal in lowering
Triglyceride level (ATPllI). A prospective large scale
study should be performed to assess the pattern use
of statins with respect to clinical settings in
Indonesia, thus, the efficacy and other beneficial
aspects of statins could be rigorously measured.
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